Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma
Status:
Suspended
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well daratumumab works in treating transplant-eligible
patients with multiple myeloma. Daratumumab is a monoclonal antibody that may interfere with
the ability of cancer cells to grow and spread.